Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis
Semaglutide shows promise for resolving fatty liver inflammation in people with metabolic dysfunction, though longer studies are needed to confirm benefits for advanced scarring.
This updated meta-analysis of 10 studies (n=1908) demonstrates semaglutide significantly resolves steatohepatitis and improves imaging/biochemical markers in MASLD/MASH, but pooled fibrosis improvement did not reach statistical significance, likely reflecting study duration and disease stage limitations. The findings support semaglutide's role for non-cirrhotic MASH while underscoring the need for longer trial endpoints to capture fibrosis regression.
What the study was
- Study design
- Systematic review and meta-analysis (PRISMA, PROSPERO registered)
- Population
- Adults with MASLD/MASH (metabolic dysfunction-associated steatotic/steatohepatitis liver disease)
- Sample size
- 1908
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British Journal of Clinical Pharmacology
Why it surfaced
Updated meta-analysis (n=1908, 10 studies, PROSPERO registered) provides the strongest pooled evidence to date on semaglutide in MASH. Clinically relevant nuance: steatohepatitis resolution is strong (OR 3.48) but fibrosis improvement is non-significant in pooled data, informing expectations for the ongoing ESSENCE Phase 3 trial.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.